Drug Discovery · Shanghai, China · Founded 2019 · Privately Held (backing)
Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. CORXEL Pharmaceuticals is based in Shanghai, China and was founded in 2019. Its last reported valuation was $475 million in Sep 2024. It has raised $452 million across 1 recorded round; the latest was a $287 million Series D1 in Jan 2026.
Last reported valuation
$474.9M
Oct 2026
Priced at
—
Total raised
$451.8M
Last round
Later Stage VC (Series D1)
Jan 2026
Team — not yet on record
No current team members for CORXEL Pharmaceuticals are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of CORXEL Pharmaceuticals with a free account
·The complete investor list: 13 names
·Watch CORXEL Pharmaceuticals: the Monday email on marks, rounds and moves
